BSc, Biology (Univ. Notre Dame)
PhD, Pharmacology (Univ. Michigan)
Awards and Recognitions
2014/7 – 2016/7: Elected Vice-President and President, American Association of Veterinary Parasitologists
2014/7: Merial-AAVP Distinguished Veterinary Parasitologist Award, American Association of Veterinary Parasitologists
2012/9: 2019/9 Tier I Canada Research Chair in Parasite Biotechnology
2012/7: Bueding-von Brand Award, American Society of Parasitologists
2010/9: Distinguished Alumnus Award, University of Michigan Department of Pharmacology
Consultant or advisor to:
- World Health Organization
- Bill and Melinda Gates Foundation
- Grand Challenges Canada
- US National Institutes of Health and US Food and Drug Administration
- a number of pharmaceutical and biotechnology companies.
American Association for the Advancement of Science
American Society of Parasitologists
American Association of Veterinary Parasitologists
American Heartworm Society
Tim Geary began his studies on the pharmacology of antiparasitic drugs as a postdoctoral fellow at Michigan State University, working on chemotherapy of malaria in the lab and in the field in Sudan. While at The Upjohn Company in Kalamazoo, he was privileged to lead a team in antiparasitic drug discovery. Following the acquisition of the company by Pfizer, Professor Geary joined the Institute of Parasitology at McGill in 2005 as a Tier I Canada Research Chair; he became Director of the Institute in 2007. His research program includes projects on genomic and proteomic analysis of the host-parasite interface, especially filarial and gastrointestinal nematode infections. He continue to pursue research in antiparasitic drug discovery and development. In conjunction with colleagues, Professor Geary operated an African-centered research program for the discovery of drugs for neglected tropical diseases and is currently involved in efforts to repurpose the antiparasitic drug flubendazole for use in filarial infections of humans, such as onchocerciasis and lymphatic filariasis (elephantiasis). On the veterinary side, his lab is investigating resistance in heartworms to drugs used to prevent Dirofilaria immitis infection in dogs.
Professor Geary's laboratory is engaged in the analysis of helminth parasite ligand-gated ion channels as targets for antiparasitic drugs, on the development of new formulations of flubendazole for human filariases, on the molecular language used to establish the host-parasite interface and determine the outcome of infection, on drug resistance in canine heartworms populations, and on the development of a vaccine for bovine cryptosporidiosis.